Skip to main content
194 search results for:

Fatigue 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 20-10-2023 | Prostate cancer | News | Article

    Enzalutamide use supported for biochemically recurrent prostate cancer

    The most frequent AEs in the enzalutamide monotherapy group were fatigue and gynecomastia, in 46.6% and 44.9%, respectively.

  2. 24-03-2020 | Guidelines | News | Article
    guidelinesWatch

    ESMO updates cancer-related fatigue recommendations

    medwireNews : An  update to the ESMO Clinical Practice Guideline on the management of cancer-related fatigue (CRF) has been published in the Annals of Oncology .

  3. 04-07-2023 | Non-small-cell lung cancer | News | Article

    Adagrasib shows intracranial efficacy in KRYSTAL-1 trial

    A total of 60% of patients needed dose modifications – reduction or interruption or both – as a result of TRAEs, and two patients discontinued treatment, one due to grade 3 acute pancreatitis and the other due to grade 2 fatigue.

  4. 30-06-2018 | Fatigue | Article

    The pathophysiology of cancer-related fatigue: current controversies

    O’Higgins CM et al. Support Care Cancer 2018; 26: 3353. doi:10.1007/s00520-018-4318-7

  5. 17-03-2023 | COVID-19 | News | Article

    Vaccination ‘protective’ against COVID-19 sequelae in people with cancer

    In all, 16.6% of patients reported at least one COVID-19 sequela at the first assessment, with the most common being respiratory sequelae and prolonged fatigue, in 9.0% and 7.0%, respectively.

  6. 10-03-2017 | Cancer care | News | Article

    Exercise, psychological interventions best option for cancer-related fatigue

    Exercise and psychological interventions effectively improve cancer-related fatigue during and after cancer treatment, with greater success than the available pharmaceutical options, study findings indicate.

  7. 17-02-2023 | Breast cancer | News | Article

    T-VEC warrants further investigation as neoadjuvant add-on in TNBC

    Neutropenia was the most common AE of grade 3–4, occurring at a rate of 17.5%, followed by anemia and fatigue, at 7.5% each.

  8. 06-08-2018 | Fatigue | Article

    Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)

    Roila F et al. Support Care Cancer 2019; 27: 1041. doi:10.1007/s00520-018-4393-9

  9. 23-10-2017 | Colorectal cancer | Article

    The effect of physical activity on fatigue among survivors of colorectal cancer: a systematic review and meta-analysis

    Brandenbarg D, Korsten JHWM, Berger MY & Berendsen AJ. Support Care Cancer 2018; 26(2):393. doi:10.1007/s00520-017-3920-4

  10. 23-12-2017 | Renal cell carcinoma | Article

    Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial

    Zhao F et al.  Support Care Cancer 2018; 26(6): 1889-1895. doi:10.1007/s00520-017-4027-7

  11. Small effect of disease, treatment on Hodgkin’s lymphoma-related fatigue

    medwireNews: Persistent fatigue, long after completion of treatment, is common in Hodgkin’s lymphoma survivors, and is largely unrelated to disease stage and treatment type.

  12. 09-09-2022 | ESMO 2022 | Conference coverage | Article

    Sacituzumab govitecan boosts HR+, HER2– advanced breast cancer OS

    For instance, the median time to deterioration of the EORTC QLQ-C30D global health and fatigue scores was significantly longer with sacituzumab govitecan than chemotherapy, at 4.3 versus 3.0 months and 2.2 versus 1.4 months, respectively.

  13. 08-09-2022 | Non-small-cell lung cancer | News | Article

    Pooled data support nivolumab–ipilimumab tolerability in metastatic NSCLC

    The most frequent TRAE was diarrhea, which occurred at any grade in 20.4% of participants and at grade 3 or 4 in 2.4%, followed by fatigue (17.5% and 1.8%, respectively), pruritus (16.7% and 0.6%), and rash (13.9% and 1.4%).

  14. 22-06-2022 | Prostate cancer | News | Article

    Enzalutamide during active surveillance may delay prostate cancer progression

    The most common any-grade AE in the enzalutamide group was fatigue, observed in 55.4% of patients, followed by gynecomastia (36.6%), nipple pain (30.4%), breast tenderness (25.9%), and erectile dysfunction (17.9%).

  15. 07-06-2022 | ASCO 2022 | Conference coverage | Article

    NADIM II validates use of neoadjuvant nivolumab–chemo use in stage IIIA–B NSCLC

    Febrile neutropenia was the most common event of grade 3 or 4 in the combination arm, experienced by 7.1% of patients, followed by fatigue and diarrhea, each in 3.5%.

  16. 04-06-2022 | ASCO 2022 | Conference coverage | Article

    No benefit of maintenance cabozantinib in unselected patients with mUC

    With regard to the toxicity profile, patients in the cabozantinib group were significantly more likely than those in the placebo group to experience any-grade fatigue (56.7 vs 32.2%), hypertension (43.3 vs 12.9%), diarrhea (40.0 vs 6.5%), anorexia (30.0 vs 9.7%), rash (26.7 vs 3.2%), hypothyroidism (20.0 vs 3.2%), and neutropenia (16.7 vs 3.2%).

  17. 05-06-2022 | ASCO 2022 | Conference coverage | Article

    More support from COSMIC-021 for cabozantinib–atezolizumab potential in advanced UC

    The most frequently observed grade 3–4 TRAE was amylase increase (7%) among cisplatin-ineligible patients, alanine aminotransferase increase (10%) among those who were cisplatin eligible, and amylase increase and fatigue (each in 6%) among ICI-treated patients.

  18. 09-05-2022 | ESMO Breast 2022 | Conference coverage | Article

    Trastuzumab deruxtecan CNS activity demonstrated in HER2-positive breast cancer

    Bartsch said that “no new safety signals were observed and as you would expect with trastuzumab deruxtecan, the main toxicity consisted of anemia, neutropenia, fatigue, and nausea.”

  19. 26-04-2022 | Renal cell carcinoma | News | Article

    Cabozantinib shows promise for untreated collecting duct RCC

    There were six AEs of grade 3 – two cases each of arterial hypertension and fatigue, and one each of pulmonary thromboembolism and bleeding – but there were no grade 4 or 5 AEs.

  20. 08-04-2022 | Breast cancer | News | Article

    monarchE PRO data bolster adjuvant abemaciclib use in early breast cancer

    The mean scores for certain ET symptoms, namely arthralgia and hot flushes, as well as for fatigue were similarly comparable between the treatment arms during the course of the study.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.